Its developer Beijing Biological Products Institute, a unit of Sinopharm subsidiary China National Biotec Group (CNBG), said that it had applied to the National Medical Products Administration for conditional approval of the vaccine. CNBG has another vaccine in late-stage trials and both have been approved for emergency use in China though studies have not been completed.